Ventyx Biosciences (NASDAQ:VTYX) slid 10% on Tuesday after the biotech firm said it will postpone the interim analysis from its Phase 2 study in recurrent pericarditis until the first quarter of 2026.

The California-based drug developer, which is working on oral treatments targeting inflammation-driven diseases, updated its previous timeline for the release of topline findings. The company now expects to share interim data during its R&D Day planned for early 2026.

CEO Raju Mohan said the revised schedule represents a “modest shift” from earlier expectations but creates room to add dose-ranging work using a new once-daily version of the drug within the ongoing Phase 2 trial. Mohan also noted that opening additional sites in Canada, the EU and the UK should help speed up preparations for Phase 3.

The Phase 2 trial is studying VTX2735, Ventyx’s peripherally restricted NLRP3 inhibitor, in patients suffering from recurrent pericarditis — a chronic inflammatory condition affecting the membrane around the heart that can cause intense chest pain and cardiac complications.

Ventyx also expanded its advisory team, naming Mark McKenna — founder and CEO of Mirador Therapeutics — as Strategic Advisor, along with Dr. Peter Libby of Mass General Brigham Heart & Vascular Institute as Clinical Advisor.

Beginning in December, the company plans to transition the study to a once-daily dosing schedule. The primary endpoint will continue to be evaluated at week 6, while the extension phase has been lengthened to run through 24 weeks.

Ventyx Biosciences stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.